Bristol-Myers Squibb Company Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics, Inc.

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino (HSR) waiting period for its tender offer for ZymoGenetics, Inc. (NASDAQ: ZGEN) has expired.

MORE ON THIS TOPIC